Advances in Therapeutics for Retinal Degeneration
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".
Deadline for manuscript submissions: 31 July 2025 | Viewed by 300
Special Issue Editor
Interests: retinitis pigmentosa; glaucoma; neuroinflammation; neurodegeneration; neuroprotection; optogenetics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Retinal degeneration is an irreversible vision loss caused by various disease conditions such as retinitis pigmentosa and age-related macular degeneration. These diseases affect millions of individuals worldwide. Despite the advancing knowledge on the molecular mechanisms of retinal degeneration, there is currently no effective therapy that stops retinal degeneration or restores vision for patients with retinal degeneration, suggesting an urgent need for developing novel treatment strategies. The aim of this Special Issue is to gather original research and reviews based on the current studies regarding therapy approaches and cellular and molecular mechanisms of retinal degeneration diseases. Relevant topics for this Special Issue include but are not limited to the following: cellular and molecular mechanisms of retinal degeneration diseases, novel approaches for neuroprotection, and potential treatments for retinal degeneration diseases.
Prof. Dr. Bin Lin
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- neuroinflammation
- apoptosis
- metabolic and oxidative stress
- neuroprotection
- molecular and cellular pathways
- therapeutic strategies
- molecular and cellular targets
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
